OATP1B1 and tumour OATP1B3 modulate exposure, toxicity, and survival after irinotecan-based chemotherapy

BACKGROUND: Treatment of advanced and metastatic colorectal cancer with irinotecan is hampered by severe toxicities. The active metabolite of irinotecan, SN-38, is a known substrate of drug-metabolising enzymes, including UGT1A1, as well as OATP and ABC drug transporters. METHODS: Blood samples (n=1...

Descripción completa

Detalles Bibliográficos
Autores principales: Teft, W A, Welch, S, Lenehan, J, Parfitt, J, Choi, Y-H, Winquist, E, Kim, R B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453959/
https://www.ncbi.nlm.nih.gov/pubmed/25611302
http://dx.doi.org/10.1038/bjc.2015.5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453959/
https://www.ncbi.nlm.nih.gov/pubmed/25611302
http://dx.doi.org/10.1038/bjc.2015.5

Ejemplares similares